Quick Answer
Taysha Gene Therapies, Inc. reported Research And Development Expense of $86.40 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed an increase of +30.9% in Research And Development Expense from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: $987.0 thousand | Q1 2020: $5.51 million | Q2 2020: $3.06 million | Q3 2020: $11.06 million | Q1 2021: $23.85 million | Q2 2021: $30.64 million | Q3 2021: $39.53 million | Q1 2022: $38.18 million | Q2 2022: $23.51 million | Q3 2022: $16.77 million | Q1 2023: $12.51 million | Q2 2023: $19.79 million | Q3 2023: $11.79 million | Q1 2024: $20.66 million | Q2 2024: $15.07 million | Q3 2024: $14.95 million | Q1 2025: $15.57 million | Q2 2025: $20.14 million | Q3 2025: $25.75 million.
- Over the full 6 years of available data (2020 to 2025), Taysha Gene Therapies, Inc.'s Research And Development Expense has grown by 170.9%.
- Historical annual values: Fiscal year 2025: $86.40 million | Fiscal year 2024: $66.00 million | Fiscal year 2023: $56.78 million | Fiscal year 2022: $91.17 million | Fiscal year 2021: $131.94 million | Fiscal year 2020: $31.89 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: